ImmunoGen Inc.
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
605 articles about ImmunoGen Inc.
-
ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Dec 06, 2021
12/6/2021
ImmunoGen, Inc. announced the closing of its previously announced underwritten public offering of 17,486,364 shares of its common stock, which reflects the exercise in full by the underwriters of their option to purchase up to 5,850,000 additional shares of common stock, and pre-funded warrants to purchase 27,363,636 shares of its common stock.
-
Exceeding Expectations, ImmunoGen Eyes 2022 Approval for Ovarian Cancer Drug Mirvetuximab Soravta...
12/1/2021
ImmunoGen shares positive results from its Phase III SORAYA trial, which is evaluating the use of mirvetuximab soravtansine for treating ovarian cancer. -
ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
11/30/2021
ImmunoGen Inc. today announced positive top-line data from the pivotal SORAYA trial evaluating the safety and efficacy of mirvetuximab soravtansine (mirvetuximab) monotherapy in patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer who have been previously treated with Avastin® (bevacizumab).
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 24, 2021
11/24/2021
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on November 22, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 327,700 shares of its common stock to ten new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan.
-
BioSpace Movers & Shakers, Nov. 19
11/19/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
ImmunoGen Appoints Tracey L. McCain, Esq. to Its Board of Directors
11/17/2021
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Tracey L. McCain, Esq. to its Board of Directors.
-
ImmunoGen Appoints Kristen Harrington-Smith as Senior Vice President and Chief Commercial Officer
11/16/2021
ImmunoGen Inc. today announced that Kristen Harrington-Smith has been appointed Senior Vice President and Chief Commercial Officer.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 16, 2021
11/16/2021
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that in connection with the appointment of Kristen Harrington-Smith as ImmunoGen’s Senior Vice President and Chief Commercial Officer, the Company granted to Ms. Harrington-Smith awards of non-qualified stock options and restricted stock units, under the ImmunoGen, Inc. Inducement Equity Incentive Plan.
-
ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH
11/4/2021
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced initial safety and efficacy findings from its Phase 1b/2 study of IMGN632 in combination with Vidaza® and Venclexta® in patients with relapsed/refractory acute myeloid leukemia.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 02, 2021
11/2/2021
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on October 29, 2021 the compensation committee of the Company’s Board of Directors granted a non-qualified stock option award to purchase 8,400 shares of its common stock to a new employee under the ImmunoGen, Inc. Inducement Equity Incentive Plan.
-
ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results
10/29/2021
We look forward to announcing top-line data from our pivotal SORAYA trial this quarter, including data on the primary endpoint of overall response rate and key secondary endpoint of duration of response.
-
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results
10/14/2021
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, October 29, 2021 to discuss its third quarter operating results
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2021
10/1/2021
ImmunoGen Inc. announced that on September 30, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 64,500 shares of its common stock to three employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan.
-
Celyad is focusing on advancing chimeric antigen receptor T cell (CAR T) therapies.
-
ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors
9/22/2021
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Helen M. Thackray, MD, FAAP to its Board of Directors.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 02, 2021
8/2/2021
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on July 30, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 59,700 shares of its common stock to two employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan.
-
ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results
7/30/2021
Compelling Final Data from FORWARD II Study Combining Mirvetuximab Soravtansine with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status, Presented at ASCO
-
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2021 Operating Results
7/15/2021
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 30, 2021 to discuss its second quarter operating results.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 01, 2021
7/1/2021
ImmunoGen Inc. announced that on June 30, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 67,900 shares of its common stock to four employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2021
6/1/2021
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on May 28, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 89,800 shares of its common stock to four employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan.